Table 2.

Associations Between Baseline Renal Function and Primary and Clinical Endpoints (Combined High-dose Spironolactone and Usual Care Groups)

Primary Endpoint	Unadjusted Change (95% CI); P value	Adjusted Change (95% CI); P value*
Absolute change in log NT-proBNP
GFR ≤50	0.37 (0.20, 0.55); <0.001	0.22 (0.01, 0.43); 0.041
GFR 51-71	0.30 (0.10, 0.50); 0.004	0.23 (0.01, 0.45); 0.041
GFR ≥72	Referent	Referent
Clinical Endpoints	Unadjusted Hazard Ratio (95% CI); P value	Adjusted Hazard Ratio (95% CI); P value*
30-day HF hospitalization, ED visit, or death
GFR ≤50	1.01 (0.52-1.97); 0.968	0.98 (0.43-2.21); 0.960
GFR 51-71	0.66 (0.31-1.41); 0.287	0.51 (0.22-1.18); 0.117
GFR ≥72	Referent	Referent
60-day all-cause mortality
GFR ≤50	12.75 (1.66-98.07); 0.014	12.11 (1.37-107.22); 0.025
GFR 51-71	5.14 (0.60-43.95); 0.135	5.54 (0.57-53.88); 0.140
GFR ≥72	Referent	Referent

^*Adjusted for age, systolic blood pressure, history of DM, history of atrial fibrillation, ischemic HF etiology, and proportion of patients with HF with preserved ejection fraction.

ED, emergency department; GFR, estimated glomerular filtration rate; HF, heart failure; NT-proBNP, N-terminal pro-B-type natriuretic peptide.